ADVICE AND INSTRUCTIONS TO APPLICANTS

To be used in conjunction with Academic Enhancement Grant application form

CLOSING DATE: 5PM AEDT APRIL 1, 2017

Research and Administration Coordinator
Australian and New Zealand College of Anaesthetists
research@anzca.edu.au
Ph: 61 3 8517 5336
IMPORTANT POINTS FOR COMPLETING ANZCA GRANT APPLICATIONS

- Read the ANZCA Research Grant Policy before completing the application form (http://www.anzca.edu.au/fellows/Research/anzca-research-information.html)

- An ANZCA REGKEY must be obtained and included in the header of the application form. Double-click on the header to add your REGKEY. Contact Susan Collins (email: research@anzca.edu.au) to obtain your REGKEY.

- Do not include or copy the cover sheet. Start your application with the page headed “In Confidence”.

- A font size no smaller than 10 point must be used. The minimum margin is 2cm.

- You may add rows to tables where this is allowed in these guidelines (e.g. list of chief investigators, list of current research grants). Do not exceed prescribed word/page counts. Text that exceeds prescribed word counts will not be considered

- Ensure that each page is numbered consecutively in the application.

- A written quotation for equipment costing $A10,000 or more, as requested in the budget section, must be attached to each copy of the application.

- The application must be submitted electronically via email to research@anzca.edu.au. Only files of 6MB or less will be accepted. The electronic copy of the complete application including the signature page with scanned or electronic signatures (via email)

- Electronic copies must be in PDF format (converted word files only, not scanned documents) or Microsoft word format. Note for older versions on Microsoft Word please install the official update from http://www.microsoft.com/download/en/details.aspx?id=9943. This update will allow Microsoft office 2007 save documents to .PDF format.

- The complete application must be received by the Research and Administration Coordinator by 5PM AEDT on the closing date for applications.

- Late applications WILL NOT BE ACCEPTED.

- Incomplete applications or those that do not follow these guidelines WILL NOT BE ACCEPTED.

- ANZCA cannot amend an application once it has been submitted.
A. CONDITIONS OF ANZCA ACADEMIC ENHANCEMENT GRANT

1 General
The Academic Enhancement Grant helps to establish, enhance or sustain a research program. The salary and position of the responsible investigator ("chief investigator A" [CIA]) should be reasonably assured for the duration of the grant.

2 Payment
Sums awarded will be paid upon request after January 1 each year for the duration of the grant. All payments will be made in Australian dollars, upon receipt of a fully correct tax invoice from the administering institution.

3 Conditions of professional research personnel
The conditions for professional research personnel shall be those of the institution in which the work is carried out or as the College may determine in particular circumstances. This includes annual leave and sick leave. However, the College does not provide for long service leave.

4 Alterations in research program budget
The CIA is expected to adhere to the approved research program or budget, and to notify any absences other than for short periods (e.g. three to four weeks). Full details of any proposed major alterations to either program or budget, or of any absences during the course of the grant, should be submitted in advance by the CIA to the Research and Administration Coordinator for approval by the Chair of the Research Committee (or his or her delegate).

5 Reporting requirements
Eligibility to apply for future funding will be contingent on complying with the reporting requirements of the ANZCA Grant Agreement Terms and Conditions. Unless otherwise specified, grants are awarded for the period of two calendar years following the year of the grant decision. The CIA may request in writing a time-only extension or roll-over of funds if the project is not completed at the end of the two-year period.

5.1 Progress report
The CIA is required to forward a progress report on the approved form to the College, by September 1 in each year of the award. This form can be found on the ANZCA website. If a progress report is not received by the due date, any funding for multi-year projects may be withheld and/or any future funding requested in subsequent years by the CIA may not be considered.

5.2 Final report
The CIA is required to forward a final report on the approved form to the College, within three months of the completion of the project. This form can be found on the ANZCA website. The final report must include a statement of expenditure charged to the grant. Any unexpended balance of the grant should be returned to the College and must not be used on other projects.

6 Publications and presentations
The College requires that its contribution be acknowledged in all publications and presentations of the research project, for example "This study was supported by a Grant from the ANZCA Research Foundation, Australian and New Zealand College of Anaesthetists" and that a presentation relating to the project be made at a major College meeting. A hard copy or pdf of the reprint should be sent to the Research and Administration Coordinator. If the protocol is registered with a journal or other relevant organisation, the College must receive a copy of the registration certificate.

7 Patents
Any discovery arising out of work supported by the College must not be the subject of application for patent except with the written approval of the College and the agreement of the institution in which the work is carried out.
8 Audit of research projects
In accordance with the ANZCA Academic Integrity Policy, available on the website, ANZCA reserves the right to conduct a random audit of ANZCA-funded research through the administering institution’s research office.

9 Termination of grant
A grant may be terminated if the conditions of the grant are not observed. A grant will terminate, unless other arrangements satisfactory to the College are made, if the chief investigator leaves the institution before the expiry of the grant. In such an eventuality, the recipient and the head of the department are expected to notify the College CEO. When a grant terminates any unexpended balance must be returned to the College.

B. GENERAL INFORMATION FOR APPLICANTS

1 Introduction
Funding for medical research in Australia, New Zealand, Hong Kong, Malaysia and Singapore is necessary if medical science is to maintain a high international standing. The most important single national source of funding for medical research in Australia is provided by the Commonwealth government through the Medical Research Endowment Fund, which is administered by the National Health and Medical Research Council (NHMRC). In New Zealand, funding is administered by the Health Research Council (HRC).

The NHMRC provides the opportunity for individuals or research teams to obtain support for research projects in all fields of public health, medicine and dentistry in Australia, through the Project Grant and Fellowship schemes. In New Zealand the HRC serves an equivalent role. The award of a project grant is ANZCA’s main avenue for the support of projects in biomedical research in Universities, medical schools, hospitals and other research institutions. The purpose of such schemes is to provide support for work on problems which are capable of solution in a relatively short period of time. ANZCA aims to supplement, complement, and in some cases act as an alternative to NHMRC/HRC. Wherever possible and appropriate ANZCA encourages applicants to also apply to HRC or NHMRC, or to the appropriate body in their home country.

2 Academic Enhancement Grants
The Academic Enhancement Grant is an award to an individual with an academic appointment, or an academic institution, for the support of a program of scientific investigation proposed by one of the academic staff at that institution. The academic title-holders and department must be located in Australia, New Zealand, Hong Kong, Malaysia or Singapore.

The investigation will have objectives of mutual interest to ANZCA, the recipient institution, and the investigator. Whilst the grants may specify financial support for individual professional research personnel, the institutions are responsible for administration of the award. The maximum amount available for the Academic Enhancement Grant is **$100,000**. This amount will be made available in one year, but may be apportioned in the budget over more than one year. For administrative purposes, single year grants are treated as running over two years from the start of the year in which the grant is awarded.

Awards of grants will normally be announced in September of each year. No payment of the grant will be made until written communication accepting the offer and agreeing to the conditions, and a fully correct tax invoice, are received by the College, and all necessary clearances have been obtained.

An individual may only be named as a chief investigator or professional research person on a **maximum of TWO applications** in any one year. This includes Project Grants, the Simulation/Education Grant and the Academic Enhancement Grant. It does NOT include the Douglas Joseph and Lennard Travers Professorships. However, this condition does not apply if an applicant wishes an unsuccessful professorship application to be considered for a project grant and has indicated this by ticking the box on the professorship application form. Fellows and registered trainees must be financial and in good standing with ANZCA or FPM.
3 Other funding agencies
Liaison between ANZCA and other major funding bodies, both government and private, has been established to preclude duplication of support for identical proposals, as far as possible.

4 Eligibility
Applications for Academic Enhancement grants are accepted from chief investigators, who are resident in Australia, New Zealand, Hong Kong, Malaysia and/or Singapore, and who hold ANZCA or FPM Fellowships ONLY.

The following academic title-holders in anaesthesia and/or pain medicine and related disciplines will be eligible for receipt of the grant based on the merit of the application.

The following definitions apply: A “professor” is a member of the academic staff of a university. A professor may be paid or honorary; a full professor or associate professor, or a clinical professor or clinical associate professor. A “chair” is either the head of an academic department of a university, or the holder a personal chair within a department. An “academic department” is a department within the faculty of medicine (however titled) of a university; a department within a hospital headed by a member of the academic staff of a university; or department within a hospital that includes members of the academic staff of a university who lead the academic work of the department. All other things being equal, grants will be awarded in the following order:

- Occupants of newly established chairs
- New occupants of established chairs
- Chairs commencing new initiatives
- Professors
- Associate Professors
- Clinical Professors
- Clinical Associate Professors

Reapplication within five years would normally not be considered unless exceptional circumstances exist.

The criteria for the award of the Academic Enhancement grant are:

- Research merit of the program.
- Track record of the applicant(s) and their ability to carry out the proposed research.
- Potential long-term benefits of the research program to academic endeavour of the research group and the specialty, including its ability to promote Fellows and trainees pursuing higher degrees.

5 Procedure for evaluation of grant applications
The procedure for the evaluation of ANZCA grant applications is modelled on the NHMRC review process. Each application is assessed by three reviewers, one of whom is a spokesperson appointed from the Research Committee, and who have been carefully chosen for their relevance to the particular grant application.

To assess the scientific merit of the project and to determine the ability of the investigators to carry out the research, reviewers are requested to (i) rate the grant application and (ii) provide a written report.

Applications are rated on a seven-point scale (ranging from “outstanding” through to “poor”) along a set of five criteria (track record, scientific merit of program, feasibility, international competitiveness, and benefit to the development of the research group and to the specialty in Australia, New Zealand, Hong Kong, Malaysia or Singapore).

The written report addresses the scientific merit of the application (originality of hypothesis, substantiation of objective, soundness of research plan and methodology, and feasibility of the project), the track record of the applicant, the budget and raises questions on areas of the research which require clarification, including problems and limitations likely to be encountered. The written report is forwarded to the applicant for comment. **The applicant response is limited to three pages only with a minimum 12pt font and 1.5cm margin. Pages in excess of the three page limit will not be considered.** If the applicant responses are not received by the due date, they will not be considered in the ranking of the application.
The Research Committee then considers all the materials, as presented by the spokesperson. Each member allocates a score out of seven to the grant, these scores are averaged and the final ranking of each grant application is determined. The Research Committee determines a rating score as a cut-off point, below which funding is not available. Those applications that are close to the cut-off score are considered in more detail. An application identified to receive the grant is then exhaustively reviewed to determine the level of funding to be awarded.

Applicants will be notified of the outcome in September following the Research Committee meeting. Successful grant applicants will be expected to participate in reviewing ANZCA grant applications in future years as a condition of accepting the grant.

6 Confidentiality
Applications for grants are received by ANZCA on an “IN CONFIDENCE” basis. This means that the application document will not be released other than in compliance with any waiver or consent given by the applicant.

7 Applications to Philanthropic trusts and foundations for research grants
Through the ANZCA Research Foundation, submissions will be made to the philanthropic sector from successful and highly ranked grant applications awarded through the ANZCA peer-reviewed grant process. It should be noted that approved grant funding through the peer-review process is not dependent on an application to the philanthropic sector. Final confirmation of ANZCA funding is subject to completion of any external funding applications for this project that are in progress. The aim of the Foundation submitting applications to the philanthropic sector is to continue to increase the pool of available funds for future ANZCA research projects. If an ANZCA grant application is deemed a suitable match to the specific interests of a particular trust or foundation, approval of the CIA will be sought for a submission to be made. The CIA’s input and advice would be sought during the application process. Acceptance of a philanthropic trust or foundation support will usually require acknowledgement of that support in publication or presentation of research. This is in addition to the requirement to acknowledge any support provided by ANZCA.
C. INSTRUCTIONS TO APPLICANTS FOR COMPLETING FORM

1 Scientific project title
The scientific title will be used to identify the application at all times and should accurately describe the nature of the project. Use no more than 120 characters, including spaces. Additional characters will not be recorded.

2 (a) Chief investigators
Chief investigators MUST be Fellows of ANZCA or FPM, and MUST hold an academic title (see above). Investigators who are not Fellows or academic title-holders may be named as associate investigators or professional research personnel (see below). The CIA will be regarded as the contact person for the application and will, in all instances, be assumed to be acting on behalf of, and with the concurrence of, all chief investigators named in this section. An individual may only be named as a chief investigator or professional research person on a maximum of TWO applications in any one year. This includes Project Grants, Novice Investigator Grants, the Simulation/Education Grant and the Academic Enhancement Grant. It does NOT include the Douglas Joseph and Lennard Travers Professorships. However, this condition does not apply if an applicant wishes an unsuccessful professorship application to be considered for a project grant and has indicated this by ticking the box on the professorship application form. Add more rows if necessary. Fellows must be financial and in good standing with ANZCA or FPM.

2 (b) Associate investigators
Associate investigators may be Fellows, trainees, students or professional research personnel, who assist with the research or bring a particular skill (e.g. statistics, assays) to the team. They may or may not be fully conversant with all aspects of the work. Associate investigators do not receive salary support from ANZCA. Add rows to any of the items if necessary.

3 Administering institution
The full name and full address of the institution responsible for administering the grant must appear here (e.g. Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2030). While there may be instances where a program of research is carried out in more than one location, there can be only one administering institution for each grant.

4 Institution(s) where research will be carried out
The name(s) of the department and name(s) and address(es) of the institution(s) where the proposed research will actually be undertaken is (are) required (e.g. Department of Anaesthesia, Royal Melbourne Hospital VIC 3050). Add more rows if necessary.

5 Area of research
Specify anaesthesia (01), intensive care medicine (02), pain medicine (03), perioperative medicine (04) or other (05).

6 Keywords
Select up to five keywords or phrases from the list at the end of this guide. If appropriate words are not found in the list, applicants may add their own keywords in this section. The keywords will be used to identify suitable reviewers.

7 Lay description of research
Provide a brief description of the department and/or chief investigator(s), the achievements of the department and/or chief investigator(s), and the proposed research and its significance [suitable for a media release]. No more than one page is allowed. Please include a lay title.

8 Grant synopsis
This information is used primarily to assign the application for review. This one page synopsis should describe the project and including a description of the aims, significance, context, objectives, methods and likely benefits of the research plan to the research group and the specialty.
Requested non-reviewers: Applicants preferring particular reviewers NOT to be approached to assess their application should attach a letter containing details of up to two non-requested non-reviewers. This letter should be attached to the original application only. These requests will be considered by the ANZCA Research Committee.

9 Research plan
Describe your program of research in this section. You must describe the overall program as well as the details of an initial project. Do not use more than ten pages in total, including references. Note that the minimum page margin is 2cm and the minimum font size is 10pt. Any additional pages will be removed prior to review.

You must use the headings listed below to describe your research.

9.1 Aims and significance: Use this space exclusively to describe the broad aims and potential significance of the program of research. Hypotheses to be tested must be clearly stated.

9.2 Background: Describe the significance of the broad area of research, the objectives of the research and the background including scientific aspects and how the proposal will benefit the development of your research group and/or the specialty.

9.3 Methods: Include, where appropriate, details of the experimental design at least for an initial project or projects in the area of research, and statistical methods to be used. Include sample size estimations.

9.4 Feasibility: You must provide evidence that the proposed study can proceed in a timely fashion (i.e. recruitment of participants is assured, instruments have been developed and piloted).

9.5 References: References should be provided within the ten pages. Do not attach copies of any references. Include the title of the paper when citing references to other work.

Explanatory appendices are not permissible, nor is it appropriate to use such phrases as “refer to last year’s application”.

10 Professional research personnel
Professional research personnel may include nurses, scientists, research assistants and the like. Full-time students, Fellows and trainees may not be included as professional research personnel.

Where appropriate, request for professional salaries should be in accordance with the official salary scales (such as NHMRC or nursing scales). Personnel should be names where known. Where the personnel are unknown the required salary should be determined on the basis of the appropriate scale. Requests for new senior research officer positions only must provide a curriculum vitae with the application. Include provision for payroll tax, workers’ compensation insurance, superannuation or other institutional legal liabilities. Nursing awards may also be appropriate for calculating salaries.

Add more rows to any of the tables in this section if necessary and repeat for each named professional research person.

11 Budget Items
Please note that applications for more than the maximum amount will be returned.

The budget must be constructed in Australian dollars. The maximum amount available for the Academic Enhancement grant is $A100,000. This amount will be made available in one year, but may be apportioned in the budget over more than one year. All items, listed in the space provided, are to be classified under these headings:

11.1 Personnel: Chief investigators (who are all Fellows of ANZCA or FPM) and associate investigators may not receive salary from the Academic Enhancement grant. Requests for professional salaries including initial, promotion and renewal requests, should be in accordance with the official NHMRC or MRC designations and salary scales, or appropriate nursing awards. Include provision for payroll tax, workers’ compensation insurance, superannuation or other institutional legal liabilities and on-costs. (see also section 8)
11.2 **Equipment:** Equipment requests should not include the type of apparatus normally provided from institutional funds (such as equipment used in the normal course of patient care); requests should cover only those items individually costing over $A800, which are essential to the project. Where the cost of a specific item of equipment, plus related accessories, is in excess of $A10,000, a firm written quotation based on current prices, not incorporating any component for customs duty, must be submitted. Applicants should ensure that the institution is prepared to meet all service costs in relation to equipment awarded.

11.3 **Maintenance:** Enter those items not included within other categories, i.e. such items as equipment costing less than $A800, consumables (under major headings), printed materials, microfilms, survey or field expenses and computing charges.

11.4 **Other items:** Include all other budget items here. ANZCA will consider requests for funding for computer programming, preparation and storage of data, but will not normally provide funds for the hire of computer time on a computer within the applicant’s institution. Requests for funds for programming, preparation and data storage or the hire of external computer time must be fully justified. Funds for purchase of computer equipment and hire of computer personnel should be itemised under ‘Equipment’ and ‘Personnel’ respectively.

11.5 **Justification of budget:** It is important to note that realistic budgetary details for the whole period are provided, as no supplementary requests will be granted. A genuine assessment is therefore required for funding of the grant. Amounts requested should reflect the real needs of the project.

12 **Chief investigators**

The chief investigator(s) is (are) pivotal to the concept, design and conduct of the research, analysis of the data and/or preparation of the manuscripts. The chief investigator(s) is (are) fully conversant with all aspects of the research. Chief investigators **DO NOT** receive salary support from the Academic Enhancement grant. Salary support may only be obtained from ANZCA through scholarships.

Copy and complete item six for each named chief investigator on this application. Start each chief investigator on a new page. Add rows to any of the items if necessary.

12.1 **Contact details:** Please ensure that the details provided are complete and accurate, as this information will be used to communicate with the applicants.

12.2 **Academic qualifications/awards:** Provide details of academic qualifications including university degrees, specialist college diplomas, research or other awards or honours, the institution or body awarding the qualification and the year it was awarded.

12.3 **Current appointments:** List all current positions with the location (institution). Any changes during the lifetime of the grant relating require notification to ANZCA.

12.4 **Sources of current salary:** Include sources of salary earned during normal working hours in current academic/clinical appointments. **DO NOT** include sources of salary from private clinical work or other work performed out of hours. **DO NOT** include monetary amounts.

12.5 **Previous appointments:** Please list relevant previous positions held.

12.6 **Other research outcomes, professional, academic or related activity:** Provide any relevant information in relation to patents, commercialisation (including industry funding or IP), industry involvement etc. Briefly list any other responsibilities that will be undertaken in addition to your responsibility as a chief investigator on this grant (other research activities, peer review, research committee work, teaching, clinical practice, administration, industry consultation etc).

12.7 **Time allocation to research:** Within the current appointments and during the normal working week. Provide details of estimated percentage of working time in each category.

12.8 **Anticipated absences during grant period:** Should an investigator be absent during the project grant for a period in excess of two months, specify period of absence and give reason.
13 Department details

13.1 Background of academic department: Briefly provide details about the establishment of your academic department or the establishment of the academic appointment that you hold. List the previous incumbents in your position, if appropriate.

13.2 Current academic appointments: Summarise the current academic appointments of the chief investigators.

13.3 Academic activities of the department: Describe the academic activities of the department or chief investigator(s), in terms of collaborating with other departments, supervising research students, managing research staff, and other research activities in the university and/or institution.

14 Research support

The information sought on past, present and future support will assist ANZCA in determining the relationship between various projects and the personnel involved in them, including their time commitment. For this reason, applicants should list all projects for which their name is recorded as a chief investigator in each category.

In each category, indicate the year of application, ANZCA RegKey, NHMRC application ID etc, title of grant, chief investigator(s), time commitment of each named investigator to each grant, period of support and funds for each year. In the column headed Publications, please identify separately, by number, each publication listed by a chief investigator which has resulted directly from each project (i.e. CIA-4: the 4th publication in the list of chief investigator A publications). Do not include the same publication more than once; include only original papers published or accepted for publication in refereed journals. Add more rows to each table if necessary.

14.1 Completed grants: Details of past research grant support should encompass all projects or part projects funded over the previous five year period by all sources of grants (not including the year of application), itemising the level of support for each year. Include project grants, program grants, scholarships etc. Exclude any projects which hold a current commitment (e.g. a three year project currently in its second year), to be itemised under 13.2.

14.2 Current grants: Include details of all currently held grants, including those that have been awarded but have not yet commenced.

14.3 Requested grants: Include this application and all other grant requests relating to this program of research, as well as requests related to other research. Please provide full details of all funding from any source. Failure to disclose full information will result in the application being removed from any further consideration by ANZCA. If you apply to another funding agency after submitting this application, you must immediately notify ANZCA in writing.

15 Publications of chief investigators for track record consideration

List, and number consecutively, papers published, in press or finally accepted for publication in refereed journals, by any of the chief investigators (CIA, CIB, CIC, CID etc), in the five years prior to the year of application and in the year of application. The listing must indicate titles of papers, sequence of authors as shown in the paper, first and last pages, name, volume and date of journal; for recent papers not yet published, the date of final acceptance by the journal’s editor is required. Quality as well as quantity of publications will be considered in the assessment of grant applications. Papers in refereed journals in which the chief investigator was not co-author, but which resulted from previous grants, should be listed at the end of that chief investigator’s publications under the title “non-chief investigator papers” (e.g. papers with scientists or PhDs supported by the grant but in which the chief investigator was not an author). Documentary evidence of final acceptance by editors must be made available to ANZCA. Do not include abstracts or papers in preparation or submitted for publication but not yet finally accepted.

Publications resulting directly from a specific project must be identified in the list of completed or current grants and, where applicable, in progress reports or in summary reports, and should be identified as “CIA - 5” or “CIB -2”). Asterisk (*) a maximum of five publications per chief investigator, which are considered to best reflect research contributions to date. Please include the citation index for these five papers and the impact factor of the journal in which they were published.
16 Clearance requirements

The Research Committee strongly encourages investigators to apply for ethics committee approval for the initial project of the Academic Enhancement Grant and submit the approvals to the College by September 1. If a grant is awarded, funding will not be released until all relevant clearances for the initial project have been received by ANZCA. ANZCA reserves the right to request full ethics committee submissions and correspondence as part of the granting process. In addition, ANZCA requires that clinical trials are pre-registered with the appropriate agency (e.g. NHMRC).

16.1 Research involving humans

(i) Approval of the human research ethics committee should be sought for ALL projects in humans. In the case of audit or routine testing, the ethics committee may not require a formal application, but will provide a covering letter that must be submitted to the College. Human research, in this context, includes research involving any human tissue, no matter what the source, and also includes research in which there is any intervention (physical or psychological) in the normal lives of humans. Projects supported by ANZCA are expected to conform with the general principles outlined in the NHMRC document ‘National Statement on Ethical Conduct in Human Research’. (see NHMRC website)

(ii) Under the various privacy laws, any form of experimentation involving humans (including epidemiological research) which uses personal information that is obtained from a national or state department or agency must be considered by a human research ethics committee.

(iii) All projects involving the administration to humans of drugs, chemical agents or vaccines need to be considered by the relevant human research ethics committee (HREC) to assess the appropriateness of their use. Clearance by the HREC is not only required for projects involving the use of imported substances, but also for projects involving the experimental use of locally produced therapeutic substances. ANZCA funds will not be provided unless appropriate clearance for the use of such substances is given. In the case of multi-centred trials, approval must be obtained from the HREC of each institution involved. In the case of drugs that are not approved for use in Australia, New Zealand, Hong Kong, Malaysia and/or Singapore, approval of the appropriate authority must be obtained before funds can be released.

(iv) The official letter or statement of approval from the ethics committee must be forwarded to ANZCA no later than September 1 each year, or before a tax invoice for funds is sent to the College.

(v) ANZCA should have access, if required, to all information relating to ethical decisions arising from an application and the institutional response to the application. Provisional Clearances will not be accepted.

(vi) Under item 16.4, please summarise all the ethical implications of your research program. Do not use more than one page. Include the issues of privacy, and male-female ratios, and the cultural implications of your research (i.e. as they relate to aboriginal populations). Please refer to the NHMRC “National Statement on Ethical Conduct in Human Research”. Note that it is not sufficient to state that “the NHMRC Statement on Ethical Conduct in Human Research will be observed”. The Research Plan must include sufficient detail to enable the project to be fully assessed with respect to ethical issues by an independent Ethics Committee.

16.2 Research involving animals

(i) Projects supported by ANZCA are expected to conform with the provisions of the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, and with its general principles outlined in the Council’s document ‘Statement on Animal Experimentation’ or the New Zealand equivalent.
ANZCA requires a statement from the relevant Institutional animal ethics committee that any project involving animal experimentation has been reviewed and is approved by the Committee as complying with the Code of Practice. It is the applicant’s responsibility to ensure that a copy of his or her project application is referred to the relevant institutional animal ethics committee; it also his or her responsibility to ensure that the completed approval form is forwarded to ANZCA, no later than September 1 each year, or before the tax invoice for funds is sent to ANZCA.

ANZCA should have access, if required, to all information relating to ethical decisions arising from an application and the institutional response to that application. Please identify the institutional animal experimentation ethics committee to which the application has been or will be referred. Provisional clearances will not be accepted.

Applicants whose projects involve inbred strains of animals must take action to confirm that the genetic authenticity of the colony has been checked at appropriate intervals.

Ideally the health status of animals should be known and the colony regularly monitored for pathogens which may influence results in the investigator’s particular area of research.

Under item 16.5, please summarise all the ethical implications of your research program. Do not use more than one page. Include the issues related to the care and welfare of animals. Please refer to the “Statement on Animal Experimentation”. Note that it is not sufficient to state that “the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes will be observed”. The research plan must include sufficient detail to enable the project to be fully assessed with respect to ethical issues by an independent animal ethics committee.

Applications involving animals must contain adequate information to allow assessment of the ethical implications of experiments, particularly where significant pain and/or distress may be caused, where death is likely to occur, or where experiments in Category 4 are to be carried out.

16.3 Other Clearances

16.3.1 Genetic manipulation of organisms: Applicants proposing to undertake research involving genetically modified organisms (GMO) must ensure that all the requirements of the Gene Technology Act 2000 and the Gene Technology Regulations 2001 have been met. Information on the Act and Regulations can be found on the Office of the Gene Technology Regulator website (www.ogtr.gov.au). Applicants should seek advice from their institutional biosafety committee (or equivalent) on the level of authorisation needed for any proposed GMO research. Clearances from an institutional biosafety committee (or equivalent) must be forwarded to ANZCA prior to release of grant monies.

16.3.2 Use of carcinogenic or highly toxic chemicals: Applicants whose projects involve the use and disposal of potent carcinogenic or other highly toxic chemicals must adhere to the National Occupational Health and Safety Commission guidelines, National Code of Practice for the Preparation of Material Safety Data Sheets 2nd edition. Further information is available from the Safe Work Australian website or equivalent. Such applicants must seek clearance to be forwarded to ANZCA prior to release of grant monies.

16.4 Conflict of Interest

Applicants are NOT required to complete the questionnaire but rather are requested to read and understand the ANZCA Conflict of Interest Policy (available at: http://www.anzca.edu.au/documents/conflict-of-interest-policy) declare any conflicts, and state how such conflicts will be managed.
17 Progress report on ANZCA grant(s)
A progress report must be provided for each grant being supported by ANZCA at the time of preparing this application and which has listed, as one of the chief investigators, any of the chief investigators of this application. A separate report form should be used for each progress report. It is understood that current projects may not relate to the project proposed in this application. Failure to submit all progress reports may jeopardise its outcome. Note: progress reports are NOT required for grants commencing in the year of submission of the current proposal.

At the conclusion of support for each grant, a final report must be submitted to ANZCA. The deadline for this report is **within three months of the completion of the project**. Each applicant listed on Page two of this application who was listed as a chief investigator on any project that terminated in the December prior to submission of this application, MUST obtain copies of the terminating project’s summary report and it to this application. Failure to comply with this request may jeopardise the outcome of this application. The final report must include a statement of the expenditure charged to the grant. Unused funds may not be expended on other activities and must be returned to the College.

18 Certification by chief investigators, head of department and of institution
The application is invalid without the signature(s) of all the chief investigator(s). Academic Enhancement Grants will only be considered for support if the head of department/head of research committee certifies that the facilities available are appropriate to meet the needs of the application (e.g. adequately staffed and equipped laboratories/workshops, secretarial assistance, library resources, research/maintenance support including equipment maintenance, animal housing facilities etc).

When applicants are not formally attached to institutions, they should indicate whether they have access to appropriate facilities to undertake the research proposed.

ANZCA accepts as the head of institutions: the registrars of universities, the directors of independent institutes, and the managers/secretaries or medical superintendents of hospitals.

The head of the institution should note that Statements of Compliance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 8th (Ed) (2013) and the NHMRC Statement on Ethical Conduct in Human Research 2007 (updated May, 2015) are required to be completed and submitted to ANZCA on request. The head of the institution is also required to certify that the institution has established administrative processes for assuring sound scientific practice in accordance with the NHMRC Australian Code for the Responsible Conduct of Research.

**Checklist**
Complete checklist and add to original application.
APPENDIX: KEY WORDS AND PHRASES FOR USE IN ANZCA GRANT APPLICATIONS

These key words are phrases modified from those used by the journal Anesthesiology. If the key word or phrase that describes your work is not listed here, please list in the key word section of your application.

<table>
<thead>
<tr>
<th>STEMS</th>
<th>Key words/phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACID-BASE CHEMISTRY</td>
<td>Alcohol and alcoholism</td>
</tr>
<tr>
<td>ADDICTION AND DRUG ABUSE</td>
<td></td>
</tr>
<tr>
<td>AIRWAY and AIRWAY MANAGEMENT</td>
<td>Airway and ETT assessment</td>
</tr>
<tr>
<td></td>
<td>Cervical spine movement</td>
</tr>
<tr>
<td></td>
<td>Endotracheal tubes</td>
</tr>
<tr>
<td></td>
<td>LMA, ILMA and other supraglottic airways</td>
</tr>
<tr>
<td></td>
<td>Laryngeal and pharyngeal function and anatomy</td>
</tr>
<tr>
<td></td>
<td>Aspiration</td>
</tr>
<tr>
<td></td>
<td>Laryngoscopy, direct</td>
</tr>
<tr>
<td></td>
<td>Laryngoscopy, flexible and rigid fiberoptic</td>
</tr>
<tr>
<td></td>
<td>Lightwands and other Indirect methods</td>
</tr>
<tr>
<td></td>
<td>Lung isolation devices</td>
</tr>
<tr>
<td></td>
<td>Tracheostomy and cricothyroidotomy</td>
</tr>
<tr>
<td>AMBULATORY CARE</td>
<td>Anaesthesia ventilators</td>
</tr>
<tr>
<td>ANAESTHESIA MACHINES and CIRCUITS</td>
<td>Circuits and vaporizers</td>
</tr>
<tr>
<td></td>
<td>CO₂ absorbants and humidification</td>
</tr>
<tr>
<td></td>
<td>Waste gases and scavenging</td>
</tr>
<tr>
<td>ANAESTHETICS, GASES</td>
<td>Nitrous oxide</td>
</tr>
<tr>
<td></td>
<td>Xenon</td>
</tr>
<tr>
<td>ANAESTHETICS, INHALATION</td>
<td>Halothane, enflurane and isoflurane</td>
</tr>
<tr>
<td></td>
<td>Desflurane</td>
</tr>
<tr>
<td></td>
<td>Sevoflurane</td>
</tr>
<tr>
<td></td>
<td>Non-Immobilizers</td>
</tr>
<tr>
<td></td>
<td>Other inhalation anaesthetics</td>
</tr>
<tr>
<td></td>
<td>Anaesthetic metabolism and degradation</td>
</tr>
<tr>
<td></td>
<td>Carbon monoxide</td>
</tr>
<tr>
<td></td>
<td>Compound A and fluoride</td>
</tr>
<tr>
<td></td>
<td>MAC</td>
</tr>
<tr>
<td></td>
<td>Uptake and Distribution</td>
</tr>
<tr>
<td>ANAESTHETICS, INTRAVENOUS</td>
<td>Barbiturates</td>
</tr>
<tr>
<td></td>
<td>Benzodiazepines (and antagonists)</td>
</tr>
<tr>
<td></td>
<td>Etomidate</td>
</tr>
<tr>
<td></td>
<td>Ketamine (and related drugs)</td>
</tr>
<tr>
<td></td>
<td>Butyrophenones</td>
</tr>
<tr>
<td></td>
<td>Alpha2 agonists (as sedatives)</td>
</tr>
<tr>
<td></td>
<td>Propofol</td>
</tr>
<tr>
<td></td>
<td>Computer controlled infusions</td>
</tr>
<tr>
<td></td>
<td>Opioids (as anaesthetic supplements)</td>
</tr>
<tr>
<td>ANAESTHETICS, LOCAL</td>
<td>Bupivacaine, lignocaine or mepivacaine</td>
</tr>
<tr>
<td></td>
<td>Levobupivacaine</td>
</tr>
<tr>
<td></td>
<td>Ropivacaine</td>
</tr>
</tbody>
</table>
AUTONOMIC NERVOUS SYSTEM

- Encapsulated agents
- Other local anaesthetics
- Cardiotoxicity
- Seizures

- Baroreflexes
- Catecholamines
- Heart rate variability
- Microneurography
- Parasympathetic nervous system
- Sympathetic nervous system

AWARENESS and RECALL

- Enoxaparin and LMWH
- Heparin and protamine
- Hirudin
- Fibrinolytics
- Coagulation testing
- DIC and other coagulopathies
- Platelets and platelet function
- Aminocaproic and tranexamic acid
- Aprotinin
- Recombinant factor VIIa

BLOOD COAGULATION

- Acute normovolemic hemodilution
- Cell saver and other salvage methods
- Controlled hypotension
- Haemoglobin-based oxygen carriers
- Perfluorocarbons

BLOOD TRANSFUSION, CONSERVATION and SUBSTITUTES

- Mutation and mutagenesis

CANCER and MALIGNANCY

CARDIOVASCULAR FUNCTION, DISEASE AND MANAGEMENT

- Cardiac electrophysiology and conduction
- Cardiac rhythm and dysrhythmias
- Cardiac smooth muscle and myocyte function (in vitro)
- Cardiopulmonary bypass
- Circulatory arrest
- Circulatory physiology and hemodynamics
- Congenital heart disease and surgery
- Coronary circulation, myocardial ischemia and infarction
- Cardiac revascularization surgery (CABG etc)
- Myocardial preconditioning and protection
- Reperfusion injury
- Valvular heart disease and surgery
- Ventricular function
- Hypertension
- Pacing, pacemakers and defibrillators

CARDIOVASCULAR DRUGS

- ACE inhibitors
- Alpha2 agonists (CV Actions)
- Angiotensin receptor blockers
- Beta-Adrenergic blockers
Beta-Agonists
Calcium channel blockers
Other antiarrhythmics
Norepinephrine and epinephrine (vasopressors)
Dopamine
Dobutamine
Fenoldepa
Phosphodiesterase inhibitors
Amrinone and milrinone
Nitroprusside and nitroglycerin
Other vasopressors
Vasopressin
Statins

CELL BIOLOGY AND PHYSIOLOGY
Apoptosis
ATP and electron transport
Calcium and calcium signaling
Calcium binding proteins
Gene expression
Mitochondria

CHEMISTRY, BIOPHYSICS AND PHYSICS
Drug related
Equipment related
Procedure related
Compartment syndromes
Other

CRITICAL CARE
Burns
Trauma care

DERMATOLOGY

ECONOMICS, OR MANAGEMENT and MANPOWER
Trainee evaluation
Simulators

EDUCATION

EMBOLI and EMBOLIC DISORDERS
Amniotic fluid emboli
Fat and particulate emboli
Pulmonary thromboembolism
Venous and arterial gas emboli

ENDOCRINOLOGY
Diabetes mellitus and insulin
Oestrogen
Pheochromocytoma
Renin and angiotensin
Atrial and brain natriuretic peptides

EPIDURAL and SPINAL
Dural-puncture headache and blood patch
Neurologic symptoms and injury
Balance, posture and position sense

EQUIPMENT, TECHNOLOGY AND BIOENGINEERING
Animal care

ETHICS
Brain death and organ harvest
<table>
<thead>
<tr>
<th>Category</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Do Not Resuscitate orders</strong></td>
<td>Human studies and consent</td>
</tr>
<tr>
<td><strong>EYE</strong></td>
<td>Eye injuries and blindness</td>
</tr>
<tr>
<td></td>
<td>Eye surgery</td>
</tr>
<tr>
<td></td>
<td>Intraocular pressure</td>
</tr>
<tr>
<td><strong>FLUIDS, ELECTROLYTES and PLASMA SUBSTITUTES</strong></td>
<td>Hetastarch and pentastarch</td>
</tr>
<tr>
<td></td>
<td>Hypertonic saline</td>
</tr>
<tr>
<td></td>
<td>Osmolality and oncotic pressure</td>
</tr>
<tr>
<td></td>
<td>Serum sodium, potassium and other electrolytes</td>
</tr>
<tr>
<td></td>
<td>Lipid and intralipid</td>
</tr>
<tr>
<td><strong>GASTROINTESTINAL PHYSIOLOGY and PATHOPHYSIOLOGY</strong></td>
<td>Gastric reflux and emptying</td>
</tr>
<tr>
<td></td>
<td>Intestinal motility</td>
</tr>
<tr>
<td></td>
<td>Intestinal permeability</td>
</tr>
<tr>
<td></td>
<td>Splanchnic circulation</td>
</tr>
<tr>
<td><strong>GENDER</strong></td>
<td>Sickle cell disease</td>
</tr>
<tr>
<td><strong>GENETICS and GENETIC DISORDERS</strong></td>
<td>Genetic testing</td>
</tr>
<tr>
<td></td>
<td>Gene therapy</td>
</tr>
<tr>
<td><strong>GERIATRICS</strong></td>
<td>CT scanning</td>
</tr>
<tr>
<td><strong>HISTORY and HUMOR</strong></td>
<td>Magnetic Resonance Imaging and fMRI</td>
</tr>
<tr>
<td><strong>IMAGING</strong></td>
<td>PET scanning</td>
</tr>
<tr>
<td></td>
<td>Ultrasound</td>
</tr>
<tr>
<td></td>
<td>Xray</td>
</tr>
<tr>
<td><strong>IMMUNOLOGY, INFLAMMATION and INFECTION</strong></td>
<td>Allergy and snaphylaxis</td>
</tr>
<tr>
<td></td>
<td>Latex allergy</td>
</tr>
<tr>
<td></td>
<td>Histamine and antihistamines</td>
</tr>
<tr>
<td></td>
<td>Steroid therapy (systemic)</td>
</tr>
<tr>
<td></td>
<td>Antibiotics</td>
</tr>
<tr>
<td></td>
<td>Systemic inflammatory response/disease</td>
</tr>
<tr>
<td></td>
<td>Cytokines and interleukins</td>
</tr>
<tr>
<td></td>
<td>Tumour Necrosis Factor</td>
</tr>
<tr>
<td></td>
<td>Endotoxin and lipopolysaccarides</td>
</tr>
<tr>
<td></td>
<td>Free radicals and scavengers</td>
</tr>
<tr>
<td></td>
<td>Leukocytes, lymphocytes and macrophages</td>
</tr>
<tr>
<td></td>
<td>Phagocytosis</td>
</tr>
<tr>
<td></td>
<td>Wound infection</td>
</tr>
<tr>
<td></td>
<td>Infection control (hand washing, antiseptics etc)</td>
</tr>
<tr>
<td><strong>IONS AND ION CHANNELS</strong></td>
<td>Calcium and calcium channels</td>
</tr>
<tr>
<td></td>
<td>Potassium and potassium channels</td>
</tr>
<tr>
<td></td>
<td>Sodium and sodium channels</td>
</tr>
<tr>
<td></td>
<td>Ion transport</td>
</tr>
<tr>
<td><strong>KIDNEY and BLADDER PATHOPHYSIOLOGY</strong></td>
<td>Bladder function and urinary retention</td>
</tr>
<tr>
<td></td>
<td>Renal function testing</td>
</tr>
<tr>
<td></td>
<td>Renal failure and dialysis</td>
</tr>
</tbody>
</table>
LIVER PHYSIOLOGY and PATHOPHYSIOLOGY
Liver blood flow
Liver function tests

MALIGNANT HYPERTHERMIA
Diagnostic testing
Genetics and genotyping

METABOLISM and NUTRITION
Glucose and carbohydrate metabolism
Whole body metabolic rate
Obesity
Protein metabolism

MONITORING (CARDIORESPIRATORY)
Arterial catheters and pressure measurement
Blood volume, systemic
Systolic pressure variation
Cardiac output measurement
Central venous catheterization
Doppler, other
Doppler, precordial
Echocardiography, transoesophageal
Echocardiography, other
Electrocardiography
Expired gas analysis
Gastric tonometry
Oximetry, pulse
Oximetry, mixed venous
Oximetry, other
Pulmonary artery catheterization

MONITORING (CNS)
BIS and similar techniques
Electroencephalography (EEG)
Evoked potentials, auditory
Evoked potentials, motor
Evoked potentials, other
Evoked potentials, somatosensory
Oximetry, jugular venous
Oximetry, transcranial
Transcranial Doppler
Depth of Anaesthesia Assessment

NAUSEA and VOMITING
Antiemetics

NERVE BLOCKS
Brachial and cervical plexus blocks
Celiac plexus block
Lower extremity blocks
Intravenous regional anaesthesia
Other regional techniques
Nerve localization methods
Nerve injury and other complications
Neostigmine and anticholinesterases
Neuromuscular junction
<table>
<thead>
<tr>
<th>Section</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuromuscular monitoring</td>
<td>Nondepolarizing agents</td>
</tr>
<tr>
<td></td>
<td>Succinylcholine</td>
</tr>
<tr>
<td></td>
<td>Myaesthenia Gravis</td>
</tr>
<tr>
<td><strong>NEUROPHYSIOLOGY, BRAIN</strong></td>
<td>Blood brain barrier</td>
</tr>
<tr>
<td></td>
<td>Cerebral blood flow and volume</td>
</tr>
<tr>
<td></td>
<td>Cerebral oedema and intracranial hypertension</td>
</tr>
<tr>
<td></td>
<td>Cerebral ischemia and anoxia</td>
</tr>
<tr>
<td></td>
<td>Cerebral metabolism</td>
</tr>
<tr>
<td></td>
<td>Cerebral protection and preconditioning</td>
</tr>
<tr>
<td></td>
<td>Clinical neuroanaesthesia</td>
</tr>
<tr>
<td></td>
<td>Clinical neurology and neurologic examination</td>
</tr>
<tr>
<td></td>
<td>Head injury</td>
</tr>
<tr>
<td></td>
<td>Hippocampus and hippocampal electrophysiology</td>
</tr>
<tr>
<td></td>
<td>Intracranial pressure and intracranial hypertension</td>
</tr>
<tr>
<td></td>
<td>Neuronal electrophysiology, other</td>
</tr>
<tr>
<td><strong>NEUROPHYSIOLOGY, SPINAL CORD</strong></td>
<td>Dorsal root ganglia</td>
</tr>
<tr>
<td></td>
<td>Spinal cord electrophysiology</td>
</tr>
<tr>
<td></td>
<td>Spinal cord injury</td>
</tr>
<tr>
<td></td>
<td>Spinal cord ischemia</td>
</tr>
<tr>
<td></td>
<td>Spinal cord anatomy</td>
</tr>
<tr>
<td></td>
<td>Spinal cord protection and preconditioning</td>
</tr>
<tr>
<td><strong>NEUROPHYSIOLOGY, PERIPHERAL NERVE</strong></td>
<td>Peripheral nerve injuries</td>
</tr>
<tr>
<td></td>
<td>Growth factors</td>
</tr>
<tr>
<td></td>
<td>Nerve conduction and EMG</td>
</tr>
<tr>
<td></td>
<td>Peripheral nerve electrophysiology</td>
</tr>
<tr>
<td><strong>NEUROTRANSMISSION, TRANSMITTERS AND RECEPTORS</strong></td>
<td>Acetylcholine and receptors</td>
</tr>
<tr>
<td></td>
<td>Adenosine and receptors</td>
</tr>
<tr>
<td></td>
<td>Adrenergic agents and receptors</td>
</tr>
<tr>
<td></td>
<td>Cannabis and cannabinoid Receptors</td>
</tr>
<tr>
<td></td>
<td>Capsaicin and thermal receptors</td>
</tr>
<tr>
<td></td>
<td>Dopamine and receptors</td>
</tr>
<tr>
<td></td>
<td>GABA and receptors</td>
</tr>
<tr>
<td></td>
<td>Glutamate and receptors</td>
</tr>
<tr>
<td></td>
<td>Glycine and receptors</td>
</tr>
<tr>
<td></td>
<td>Neurokinins and receptors</td>
</tr>
<tr>
<td></td>
<td>Nitric oxide and nitric oxide Synthase</td>
</tr>
<tr>
<td></td>
<td>Opioids and opioid receptors</td>
</tr>
<tr>
<td></td>
<td>Serotonin and serotonergic receptors</td>
</tr>
<tr>
<td></td>
<td>Neurotransmitter release and reuptake</td>
</tr>
<tr>
<td><strong>NEUROTRANSMISSION and SIGNAL TRANSDUCTION</strong></td>
<td>G-proteins</td>
</tr>
<tr>
<td></td>
<td>cAMP and cGMP</td>
</tr>
<tr>
<td></td>
<td>Protein kinases</td>
</tr>
<tr>
<td><strong>OBSTETRICAL ANESTHESIA</strong></td>
<td>Caesarean section</td>
</tr>
<tr>
<td></td>
<td>Eclampsia and preeclampsia</td>
</tr>
</tbody>
</table>
Foetal monitoring and pathophysiology
Labour and delivery
Uterine and placental function
Uterine smooth muscle

OXYGEN and OXYGEN TRANSPORT
Hypoxia
Hemodilution (physiology)
Tissue oxygen tension (PtO2)
Hyperbaric oxygen

PAIN MANAGEMENT, CLINICAL
Acupuncture and accupressure
Chronic pain
Epidural and other steroid injections
Neuropathic pain and CRP
Stellate ganglion blocks
Lumbar sympathectomy
Pain assessment techniques
Patient controlled analgesia
Postoperative pain
Headache (NOT PLPH)
Herpes zoster
Intraarticular analgesia
Intrapleural and intraperitoneal local anaesthetics
Phantom limb pain
Preemptive analgesia (clinical)
TENS and related methods
Spinal cord stimulation
Epiduroscopy
Radiofrequency lesions and neurolysis

PAIN-RELATED PHARMACOLOGY
Alpha 2 Agonists (analgesics)
Aspirin and Acetaminophen
Baclofen
COX2 antagonists
Gabapentin
Neostigmine
NMDA antagonists
NSAIDs
Opioids
Opioid antagonists
Opioid tolerance
Tramadol
Nitric oxide

PAIN PHYSIOLOGY, EXPERIMENTAL
Incisional pain
Neuropathic pain
Inflammatory pain
Pain assessment techniques
Pain mechanisms, central
Pain mechanisms, peripheral
Pain mechanisms, spinal
Pain models
Preemptive analgesia (experimental)
Visceral pain

PATIENT SAFETY and MEDICOLEGAL ISSUES
Closed claims studies
Electrical and fire safety
Medicolegal matters

PAEDIATRIC ANESTHESIA and PAEDIATRICS
Neonatology

PHARMACOKINETICS and PHARMACODYNAMICS
Pharmacogenetics

PHARMACOLOGY (GENERAL)
Chronopharmacology/Chronobiology
Drug interactions
Drug metabolism
Cytochromes P450
Drug toxicity
Liposomes and microcapsule delivery systems
Osmotic pumps
Stereoisomers
Transcutaneous delivery systems
Transmucosal delivery systems

PHYSICIAN SAFETY
POSITIONING
Antidepressants

POSTOPERATIVE CARE
Anxiety and anxiolysis

PREOPERATIVE ASSESSMENT and CARE
Psychologic, psychometric and behavioural

PROSTAGLANDINS and RELATED COMPOUNDS
Testing

PSYCHOLOGY, PSYCHIATRY and BEHAVIOR
Electroconvulsive Therapy (ECT)

RESPIRATORY DISORDERS and MANAGEMENT
ARDS and lung injury
Aspiration pneumonia
Asthma and bronchospasm
Barotrauma
COPD
Extracorporeal membrane oxygenation
High frequency ventilation
Mechanical ventilation
Nitric oxide inhalation
Pneumonia and lung infections
PEEP and CPAP
Pulmonary oedema
Pulmonary function testing
Smoking

RESPIRATORY PHYSIOLOGY
Alveolar macrophage function
Control of respiration
Gas exchange
Pulmonary blood flow
Respiratory mechanics
Surfactant
Tracheal and bronchial smooth muscle
Ventilation-perfusion matching

RISK, OUTCOME and QUALITY MANAGEMENT
Patient safety and satisfaction
Quality assurance and management
Morbidity and mortality
Perioperative risk factors
Automated record keeping

SEIZURES and ANTIMONVULSANTS
Cardiac arrest and CPR
SHOCK AND RESUSCITATION
Sepsis and septic shock
Haemorrhagic and hypovolemic shock

SKELETAL MUSCLE
Circadian rhythm
SLEEP and SLEEP DISORDERS
Sleep apnoea
Sleep deprivation

STUDY DESIGN AND TECHNIQUES, LABORATORY
 Autoradiography
Brain slices
Histopathology and histochemistry
Cultured cells and tissues
Laser Doppler Flowmetry
Microdialysis
Patch clamping
PCR
Receptor binding
Recombinant methods
Transgenic and knockout animals
Isobolographic analysis
Analytic chemistry (chromatography etc)
Molecular modeling

STUDY DESIGN AND TECHNIQUES, CLINICAL
Clinical trial
Epidemiology
Mathematical modeling
Metaanalysis
Statistics
Survey

SURGERY, MISCELLANEOUS
Laparoscopy
Neurosurgery
Oral surgery
Orthopaedic surgery
Joint Replacement surgery
Otolaryngology
Plastic surgery
Aortic aneurysm (abdominal and thoracic)
Carotid endarterectomy
Thoracic anaesthesia and surgery
Vascular surgery
Other surgical procedures

TEMPERATURE REGULATION and MANAGEMENT
Hypothermia
Hyperthermia and fever
Shivering

TRANSPANTATION
Heart transplantation
Liver transplantation
Lung transplantation
Immunosuppressants

VASCULAR PHYSIOLOGY
Rheology and viscosity
Endothelium
Endothelin
Leukocyte adhesion
Nitric oxide, nitric oxide synthase and EDRF
Selectins
Vascular smooth muscle
Vascular growth factors
Vascular electrophysiology
Microcirculation